Positive response to cancer trial drug
The drug, Olaparib, either shrank or stabilised tumours in more than half of the trial group, all of whom had advanced cancers.
One patient given the treatment is still in remission after two years.
Black Friday Save 50%
SUBSCRIBEThe drug, Olaparib, either shrank or stabilised tumours in more than half of the trial group, all of whom had advanced cancers.
One patient given the treatment is still in remission after two years.
CONNECT WITH US TODAY
Be the first to know the latest news and updates
Newsletter
Get a lunch briefing straight to your inbox at noon daily. Also be the first to know with our occasional Breaking News emails.

Check out our diverse library of newsletters and get the best of the Irish Examiner delivered straight to your inbox
Saturday, November 21, 2026 - 9:00 PM
Saturday, November 21, 2026 - 9:00 PM
Saturday, November 21, 2026 - 8:00 AM
© Examiner Echo Group Limited